Ajanta Pharma Limited share price

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Midcap 150NSE: AJANTPHARMISIN INE031B01049

16 Oct 2026, 3:29 PM IST₹3,329.00▼ 30.40 (0.90%)

Market Cap₹ 41,599 Cr.
Current Price₹ 3,329.00
High / Low₹ 3,796 / 2,382
Stock P/E36.7
Book Value₹ 362
Dividend Yield1.91 %
ROCE29.4 %
ROE25.40 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 90.79
Price / Book9.19
OPM24.5 %
Debt / Equity0.06
Sales growth (5Y)13.5 %
Profit growth (5Y)10.1 %
Promoter holding54.3 %
EV / EBITDA26.3
Beta0.22
All-time high₹ 3,796

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
AJANTPHARM	-5.13%	-3.59%	+17.73%	+20.23%	+35.42%	+23.66%	+17.72%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Ajanta Pharma Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹41,599 crore.
It trades at 36.7 times its last 12 months' earnings and 9.2 times book value.
Revenue grew 13.5% a year over the last 5 years, profit 10.1% a year.
Return on equity was 25.4% and return on capital employed 29.4% in the latest year.
Debt was 0.06 times shareholders' equity.
The share price is 12.3% below its 52-week high and up 35.4% over one year.
Promoters and insiders hold about 54.3%; institutions about 24.4%.

Pros

Strong return on equity: 24.6% on average over the last 3 years.
Company is almost debt-free (debt is 0.06 times equity).
Latest quarter (Jun 2026): sales up 25% and profit up 31% from a year ago.
Institutional (FII + DII) holding has risen by 3.8 points over 3 years.

Cons

Promoter holding has fallen by 2.74 points over 3 years, to 63.47%.
Trades at 9.2 times its book value.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Ajanta Pharma Limited

Employees: 10,421
Head office: Mumbai
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Midcap 150

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Ajanta Pharma	3,329.00	36.7	41,599	1.91	334	30.89	1,626	24.82	29.4	25.4	9.19	24.5	0.06	54.29	5,453	13.5
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 65 Co.	1,909.45	34.3	8,632	0.17	680	21.70	6,020	18.81	16.4	13.2	3.86	15.1	0.21	54.54	20,499	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,021	1,028	1,105	1,054	1,145	1,187	1,146	1,170	1,303	1,354	1,375	1,422	1,626
YOY Sales Growth %	7.37%	9.63%	13.73%	19.53%	12.13%	15.38%	3.71%	11.04%	13.78%	14.08%	19.95%	21.47%	24.82%
	750	738	791	776	815	875	825	873	951	1,026	993	1,088	1,202
Material Cost %	25%	25%	27%	25%	23%	22%	22%	24%	21%	23%	21%	21%	20%
Employee Cost %	21%	22%	21%	22%	25%	22%	23%	24%	23%	23%	24%	24%	23%
Other Expenses %	28%	25%	24%	26%	23%	30%	26%	26%	29%	29%	27%	31%	30%
Operating Profit	271	291	314	278	330	311	321	297	351	328	382	333	424
OPM %	27%	28%	28%	26%	29%	26%	28%	25%	27%	24%	28%	23%	26%
Other Income	32	21	14	36	26	19	30	18	26	59	25	61	71
Interest	1	2	2	2	1	6	8	6	5	3	5	2	3
Depreciation	33	34	34	34	34	34	36	40	41	43	44	45	45
Profit before tax	269	276	291	278	322	290	307	269	331	341	359	347	447
	23%	29%	28%	27%	24%	25%	24%	16%	23%	24%	24%	23%	25%
Current tax	68	89	91	73	79	76	95	62	74	78	87	61	103
Deferred tax	-7	-9	-10	2	-3	-2	-20	-18	2	2	-2	19	10
	208	195	210	203	246	216	233	225	255	260	274	267	334
Profit to shareholders				196	238	216	233	225	255	260	274	267	330
YOY Profit Growth %	19.18%	24.71%	56.14%	65.82%	18.09%	10.84%	10.88%	11.12%	3.89%	20.19%	17.56%	18.40%	30.89%
EPS in Rs	16.53	15.51	16.68	16.10	19.54	17.27	18.60	18.00	20.44	20.83	21.91	21.35	26.75
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,015	945	1,085	926	1,077	1,129	1,102	1,014	1,209	1,220	1,207	1,211	1,489
YOY Sales Growth %		12.89%	24.05%	9.10%	6.18%	19.44%	1.53%	9.49%	12.19%	8.09%	9.50%	19.39%	23.18%
	738	672	758	699	761	826	766	764	879	931	866	972	1,092
Material Cost %	29%	25%	28%	26%	24%	24%	23%	23%	22%	24%	21%	22%	21%
Employee Cost %	19%	22%	20%	23%	25%	21%	22%	25%	23%	24%	25%	26%	24%
Other Expenses %	25%	24%	22%	26%	22%	28%	24%	27%	28%	28%	25%	33%	28%
Operating Profit	277	274	327	227	316	303	336	250	329	290	341	238	397
OPM %	27%	29%	30%	25%	29%	27%	31%	25%	27%	24%	28%	20%	27%
Other Income	31	52	14	34	28	40	33	18	41	75	26	63	71
Interest	1	2	2	1	1	1	2	1	1	1	2	-1	1
Depreciation	32	33	33	33	33	33	35	39	40	42	42	44	43
Profit before tax	275	291	305	226	311	309	332	228	329	322	322	258	423
	23%	27%	28%	28%	24%	24%	24%	15%	22%	22%	24%	23%	26%
Current tax	61	75	82	60	71	71	76	39	71	66	73	67	102
Deferred tax	3	3	3	3	3	3	3	-4	3	6	5	-7	6
	212	212	220	163	236	235	252	193	255	250	245	197	315
YOY Profit Growth %		27.02%	77.60%	38.80%	11.31%	10.65%	14.67%	18.89%	8.02%	6.19%	-2.94%	1.99%	23.73%
EPS in Rs	16.84	16.87	17.48	12.92	18.77	18.75	20.16	15.46	20.41	19.98	19.61	15.79	25.25
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	2,131	2,055	2,588	2,890	3,341	3,743	4,209	4,648	5,453	5,776
YOY Sales Growth %		-3.54%	25.91%	11.66%	15.62%	12.02%	12.45%	10.44%	17.31%
	1,472	1,489	1,905	1,891	2,412	2,959	3,037	3,389	4,058	4,309
Material Cost %	19%	19%	25%	22%	25%	28%	25%	23%	22%	21%
Employee Cost %	18%	21%	19%	19%	19%	21%	21%	23%	24%	24%
Other Expenses %	32%	33%	29%	24%	28%	30%	25%	26%	29%	30%
Operating Profit	658	566	683	999	929	783	1,172	1,260	1,395	1,467
OPM %	31%	28%	26%	35%	28%	21%	28%	27%	26%	25%
	24	21	92	26	116	99	85	95	172	217
Exceptional items			-4
Interest	0	1	12	8	10	6	7	21	16	14
Depreciation	60	72	96	116	125	131	135	144	173	176
Profit before tax	623	514	664	900	909	745	1,114	1,189	1,378	1,493
	25%	25%	30%	27%	22%	21%	27%	23%	23%	24%
Current tax	132	124	186	261	192	197	322	312	300
Deferred tax	22	3	10	-15	5	-40	-24	-44	22
	469	387	468	654	713	588	816	920	1,056	1,135
Profit to shareholders	472	384					817	920	1,056	1,131
YOY Profit Growth %		-17.43%	20.86%	39.81%	8.99%	-17.50%	38.81%	12.77%	14.73%
EPS in Rs	35.51	29.31	35.73	50.06	54.97	45.89	64.82	73.56	84.53	90.84
Dividend Payout %							79%	38%	33%

Compounded Sales Growth

5 Years:: 14%
3 Years:: 13%
TTM:: 20%

Compounded Profit Growth

5 Years:: 10%
3 Years:: 22%
TTM:: 22%

Stock Price CAGR

5 Years:: 18%
3 Years:: 24%
1 Year:: 35%

Return on Equity

4 Years:: 23%
Last Year:: 25%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	1,830	1,773	2,196	2,719	3,141	3,411	3,971	4,322	4,846	5,126
YOY Sales Growth %		-3.16%	23.91%	23.77%	15.52%	8.62%	16.41%	8.84%	12.12%
	1,284	1,291	1,664	1,802	2,250	2,712	2,852	3,117	3,648	3,861
Material Cost %	22%	22%	30%	27%	27%	29%	27%	23%	22%	22%
Employee Cost %	19%	22%	20%	18%	19%	21%	21%	23%	25%	25%
Other Expenses %	30%	29%	26%	21%	26%	29%	24%	25%	28%	29%
Operating Profit	547	481	533	917	891	699	1,119	1,205	1,198	1,265
OPM %	30%	27%	24%	34%	28%	20%	28%	28%	25%	25%
	73	102	184	104	140	133	116	120	204	235
Exceptional items			-4
Interest	0	0	9	7	9	5	7	5	3	3
Depreciation	57	70	91	111	121	127	132	140	169	172
Profit before tax	562	513	613	902	901	700	1,097	1,180	1,231	1,325
	24%	24%	28%	25%	20%	20%	26%	22%	23%	24%
Current tax	115	109	168	217	171	144	278	258	277
Deferred tax	20	13	3	10	10	-3	12	5	8
	428	392	441	676	720	559	807	917	947	1,007
Profit to shareholders	426
YOY Profit Growth %		-8.36%	12.60%	53.16%	6.54%	-22.38%	44.48%	13.58%	3.26%
EPS in Rs	32.39	29.67	33.70	51.73	55.52	43.61	64.11	73.28	75.79	80.63
Dividend Payout %						16%	80%	38%	37%

Compounded Sales Growth

5 Years:: 12%
3 Years:: 12%
TTM:: 15%

Compounded Profit Growth

5 Years:: 7%
3 Years:: 19%
TTM:: 8%

Stock Price CAGR

5 Years:: 18%
3 Years:: 24%
1 Year:: 35%

Return on Equity

4 Years:: 23%
Last Year:: 25%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	25	25	25	25
Reserves	3,363	3,542	3,765	4,502
	36	35	47	260
Long term borrowings	1
Short term borrowings	0	1	3	212
	1,255	1,036	1,177	1,368
Trade payables	423	463	454	544
Current liabilities	1,139	895	996	1,416
Total Liabilities	4,679	4,638	5,015	6,155
	1,698	1,729	1,900	2,121
Gross block	2,460	2,610	2,903	3,250
Accumulated depreciation	762	881	1,002	1,129
Goodwill & intangibles	8	15	47	42
CWIP	209	264	185	295
	2,771	2,645	2,930	3,739
Inventories	816	828	904	939
Trade receivables	1,057	1,247	1,183	1,854
Cash & equivalents	330	129	175	103
Current assets	2,834	2,731	2,843	3,735
Total Assets	4,679	4,638	5,015	6,155

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	792	785	1,157	529
Profit for the year	588	816	920	1,056
Working capital changes	67	-100	179	-653
Direct taxes paid	-151	-312	-323	-359
	-560	65	-377	-429
Fixed assets purchased	-174	-152	-318	-365
Fixed assets sold	1	13	1	5
Investments purchased	-1,663	-2,080	-2,761	-2,660
Investments sold	1,276	2,257	2,664	2,549
	-108	-1,051	-733	-168
Repayment of borrowings	-0
Interest paid	-2	-4	-17	-13
Dividends paid	-90	-642	-349	-350
Net Cash Flow	124	-201	47	-68
Free Cash Flow	618	633	839	164

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	23.1%	17.9%	19.3%	23.4%	0.0%	0.0%	23.5%	25.0%	25.4%
Operating margin	30.9%	27.6%	26.4%	34.6%	27.8%	20.9%	27.8%	27.1%	25.6%
Net margin	22.0%	18.8%	18.1%	22.6%	21.3%	15.7%	19.4%	19.8%	19.4%
Interest coverage	1,519.41	444.34	56.75	109.85	90.16	128.61	155.50	58.36	86.52
Tax rate	24.7%	24.8%	29.6%	27.4%	21.6%	21.1%	26.7%	22.6%	23.3%
Book value / share	₹154	₹171	₹198	₹230	₹253	₹268	₹282	₹302	₹361

Balance-sheet ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE	21.2%	30.0%	30.1%	29.4%
Debt / equity	0.01	0.01	0.01	0.06
Current ratio	2.49	3.05	2.85	2.64
Debtor days	104	109	94	125
Inventory days	267	271	293	275
Days payable	138	152	147	159
Cash conversion cycle	233	228	240	241
Working capital days	167	161	147	157

ROE = profit for shareholders ÷ average net worth (paid-up capital + reserves, from each year's March results filed with NSE). Interest coverage = (profit before tax + interest) ÷ interest. ROCE = EBIT ÷ (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; working capital days = (current assets − current liabilities) ÷ sales × 365. Balance-sheet ratios are shown for the years whose full balance sheet is available (Yahoo Finance and NSE filings from FY2025).

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 63.47%
FIIs 7.63%
DIIs 21.94%
Public 6.96%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	66.21%	66.21%	66.27%	66.26%	66.26%	66.26%	66.26%	66.25%	66.25%	66.25%	63.48%	63.47%
	9.11%	8.54%	8.36%	9.11%	9.26%	8.86%	8.86%	8.53%	7.98%	8.26%	7.68%	7.63%
Foreign portfolio investors (Cat. I)	8.89%	8.34%	8.12%	8.79%	8.96%	8.58%	8.56%	8.15%	7.70%	7.88%	7.37%	7.31%
Foreign portfolio investors (Cat. II)	0.22%	0.20%	0.24%	0.32%	0.30%	0.28%	0.30%	0.38%	0.27%	0.38%	0.31%	0.31%
	16.68%	17.49%	17.41%	17.10%	17.02%	17.48%	17.50%	17.90%	18.58%	18.37%	21.80%	21.94%
Mutual funds	13.86%	14.76%	14.84%	14.93%	14.89%	15.13%	14.72%	14.67%	15.49%	15.22%	18.10%	17.95%
Insurance companies	2.15%	2.16%	2.20%	1.57%	1.48%	1.58%	2.01%	2.64%	2.65%	2.70%	3.29%	3.58%
Alternative investment funds	0.66%	0.56%	0.37%	0.59%	0.65%	0.77%	0.77%	0.59%	0.44%	0.44%	0.41%	0.41%
Government			0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
	8.01%	7.76%	7.94%	7.52%	7.45%	7.39%	7.38%	7.32%	7.19%	7.12%	7.03%	6.96%
Retail (up to ₹2 lakh)	6.47%	6.31%	6.48%	6.03%	5.98%	5.95%	5.90%	5.89%	5.80%	5.71%	5.71%	5.57%
HNIs (above ₹2 lakh)	0.60%	0.60%	0.60%	0.68%	0.68%	0.68%	0.68%	0.64%	0.64%	0.64%	0.55%	0.64%
NRIs	0.33%	0.32%	0.31%	0.31%	0.32%	0.31%	0.31%	0.31%	0.30%	0.31%	0.30%	0.29%
Bodies corporate	0.28%	0.24%	0.25%	0.21%	0.19%	0.17%	0.22%	0.18%	0.17%	0.17%	0.17%	0.18%
IEPF	0.09%	0.09%	0.09%	0.09%	0.09%	0.09%	0.09%	0.09%	0.09%	0.10%	0.10%	0.09%
No. of Shareholders	54,351	55,488	70,316	64,315	66,896	70,827	68,882	67,785	65,409	67,955	65,296	61,923

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Ajanta Pharma

Holder (above 1%)	Stake
Kotak Flexicap FundMutual fund · see the fund house	3.22%
Uti-Flexi Cap FundMutual fund	2.97%
Nippon India Small Cap FundMutual fund	2.79%
Aditya Birla Sun Life Midcap FundMutual fund	2.22%
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110Insurance	1.91%
Canara Robeco Small Cap FundMutual fund	1.40%
Hdfc Large And Mid Cap FundMutual fund · see the fund house	1.01%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 17.95% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 5 Aug 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Ajanta Pharma Limited

What is the share price of Ajanta Pharma Limited today?

Ajanta Pharma Limited (AJANTPHARM) last traded at ₹3,329.00 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Ajanta Pharma Limited?

About ₹41,599 crore at the latest price.

What is the P/E ratio of Ajanta Pharma Limited?

About 36.7 times its earnings over the last 12 months.

Is Ajanta Pharma Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Ajanta Pharma Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Ajanta Pharma Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Ajanta Pharma Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Balance-sheet ratios

Shareholding Pattern

Mutual funds & institutions holding Ajanta Pharma

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Ajanta Pharma Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next